Price
CHART BY
Frequently asked questions
What is Aurinia's market capitalization?
The market capitalization of Aurinia is $1.59B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Aurinia's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Aurinia is 28.25. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Aurinia?
Aurinia's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.428. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Aurinia's stock?
Currently, 7 analysts cover Aurinia's stock, with a consensus target price of $11.71. Analyst ratings provide insights into the stock's expected performance.
What is Aurinia's revenue over the trailing twelve months?
Over the trailing twelve months, Aurinia reported a revenue of $260.11M.
What is the EBITDA for Aurinia?
Aurinia's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $102.23M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Aurinia?
Aurinia has a free cash flow of $92.29M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Aurinia have, and what sector and industry does it belong to?
Aurinia employs approximately 130 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Aurinia's shares?
The free float of Aurinia is 118.78M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.59B
- EPS (TTM)
- $0.428
- Free Float
- 118.78M
- P/E ratio (TTM)
- 28.25
- Revenue (TTM)
- $260.11M
- EBITDA (TTM)
- $102.23M
- Free Cashflow (TTM)
- $92.29M
Pricing
- 1D span
- $11.96$12.18
- 52W span
- $6.42$12.53
Analyst Ratings
The price target is $11.71 and the stock is covered by 7 analysts.
Buy
6
Hold
1
Sell
0
Information
Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.
- Employees
- 130
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- CA05156V1022
- Primary Ticker
- AUPH
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet